The Seroconversion Rate of Hepatitis A Virus Vaccination among Patients with Hepatitis B Virus-Related Chronic Liver Disease in Korea
Gut and Liver
; : 217-220, 2011.
Article
em En
| WPRIM
| ID: wpr-118223
Biblioteca responsável:
WPRO
ABSTRACT
BACKGROUND/AIMS: The aim of this study was to evaluate the seroconversion rate of a hepatitis A virus (HAV) vaccination in patients with hepatitis B virus (HBV)-related chronic liver disease (CLD). METHODS: Analyses were conducted using clinical records from 94 patients with chronic HBV infection who were seronegative for IgG anti-HAV antibodies between September 2008 and June 2009. Two doses of an HAV vaccine were administered 24 weeks apart. A third vaccine dose was administered only for patients seronegative for anti-HAV antibodies at week 48. RESULTS: The seroconversion rate of anti-HAV following the two-dose vaccination was 86.17%. The seroconversion rate of anti-HAV was not significantly different according to age or status of liver disease. The rate was higher in female than in male patients. A third HAV vaccine dose was administered to 13 patients seronegative for anti-HAV after the two-dose regimen, and 84.62% of these patients showed seroconversion at week 72. CONCLUSIONS: HAV vaccination is effective in most Korean patients with HBV-related CLD, and it might be necessary to evaluate three-dose vaccination approach for non-responders to the conventional regimen to maximize the success of an HAV vaccination program.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Imunoglobulina G
/
Vírus da Hepatite B
/
Vacinação
/
Hepatite B Crônica
/
Vírus da Hepatite A
/
Anticorpos Anti-Hepatite A
/
Hepatite
/
Hepatite A
/
Hepatite B
/
Coreia (Geográfico)
Limite:
Female
/
Humans
/
Male
País/Região como assunto:
Asia
Idioma:
En
Revista:
Gut and Liver
Ano de publicação:
2011
Tipo de documento:
Article